TLR7/8 Agonist - Imidazoquinoline compound

R848 (Resiquimod) is an imidazoquinoline compound with potent anti-viral activity. This low molecular weight synthetic molecule activates immune cells via the TLR7/TLR8 MyD88-dependent signaling pathway [1, 2].

Recently, R848 was shown to trigger NF-κB activation in cells expressing murine TLR8 when combined with poly(dT) [3].

Unlike other commercially available R848 preparations, InvivoGen's R848 is water soluble, validated for TLR7/8 potency and tested to ensure the absence of TLR2 or TLR4 contamination.

References:

1. Hemmi H. et al., 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 3(2):196-200.
   2. Jurk M. et al. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R848. Nat Immunol, 3(6):499.
   3. Gorden KKB. et al., 2006. Cutting Edge: Activation of Murine TLR8 by a Combination of Imidazoquinoline Immune Response Modifiers and PolyT Oligodeoxynucleotides J. Immunol., 177: 6584 - 6587